Close menu




Biotechnology

Photo credits: pixabay.com

Commented by Fabian Lorenz on July 23rd, 2025 | 07:10 CEST

TAKEOVER SPECULATION! Barrick Mining, Evotec, Desert Gold

  • Mining
  • Gold
  • Biotechnology
  • Takeover

Just like the high prices, takeover speculation in the gold sector is also continuing. Desert Gold is repeatedly mentioned as a candidate. With its exciting acquisition in West Africa, the explorer has diversified and made itself even more attractive to a large corporation. Perhaps Barrick? The heavyweight is currently focusing on its ore mines and selling smaller projects. It could then expand again in the gold sector, and Desert certainly fits in regionally. In the biotech sector, Evotec has long been rumored as a takeover candidate. Following the latest revenue warning, this is likely the only hope for investors to achieve short-term returns. Or was the price slide exaggerated?

Read

Commented by Stefan Feulner on July 22nd, 2025 | 07:15 CEST

Netflix, NetraMark, Novo Nordisk – Positive signals

  • Biotechnology
  • Biotech
  • Pharma
  • Streaming

So much for the old saying: "Sell in May and go away". If investors had followed this well-known stock market adage, they would have missed out on some significant gains in 2025. Instead, the world's most important indices, such as the Dow Jones, S&P 500, and NASDAQ, are close to their historic highs. And there is no sign of a summer slump, as the first-half earnings season kicked off last week. Despite already high valuations, further price gains could follow due to the positive market sentiment.

Read

Commented by Armin Schulz on July 17th, 2025 | 07:05 CEST

Bayer, NetraMark, Evotec: How AI Research is accelerating returns and could optimize your portfolio

  • AI
  • Biotechnology
  • Biotech
  • Pharma

In 2025, the healthcare industry is undergoing a radical transformation driven by AI and advanced technologies. While pharmaceutical giants struggle with cost pressures and regulatory hurdles, algorithms are revolutionizing drug development by decoding clinical data in record time and enabling personalized therapies. In this period of disruption, innovative strength will determine victory or decline. Three companies are at the forefront of this shift: Bayer, with its broad portfolio; NetraMark, leveraging AI-powered data analysis; and Evotec, with its disruptive research collaborations. Find out what is currently driving these stocks.

Read

Commented by Armin Schulz on July 16th, 2025 | 07:10 CEST

Novo Nordisk, BioNxt Solutions, BioNTech – How to heal your portfolio with the 2025 healthcare revolution

  • Biotechnology
  • Biotech
  • Healthcare
  • healthtech

The global healthcare system is facing a turning point in 2025. Climate change, chronic diseases, and the scars left by pandemics are challenging existing systems, while digitalization and AI are rapidly advancing new therapies. Governments are investing billions in modern healthcare infrastructure, but debates about data protection and scheduling doctor's appointments are escalating. While the WHO warns of stagnation, groundbreaking alliances between research and industry are emerging. This is precisely where Novo Nordisk, BioNxt Solutions, and BioNTech come in with visionary technologies that not only heal but also open up opportunities for investors.

Read

Commented by André Will-Laudien on July 15th, 2025 | 07:30 CEST

Bitcoin and exchanges in IPO and hysteria mode! AI millions from NetraMark Holdings, Clara Technologies, BitMine, and D-Wave

  • Biotechnology
  • Biotech
  • AI
  • Innovations
  • computing
  • Bitcoin

The recent IPOs on the NASDAQ show just how quickly innovations can materialize. No sooner are they listed than they skyrocket, because what is new must be good! Or is it? From a distance, stock market professionals are beginning to wonder whether everything is still above board. The crypto company BitMine, for example, gained 2,000% within two weeks, only to lose a third of its value after announcing a USD 2 billion capital increase. Clara Technologies debuted on the stock market in January with prices around CAD 0.50. By the end of last week, the share price had exploded to around CAD 16, a 32-fold increase. Our advice: Investors should examine business models very carefully before entering the ring. AI newcomer NetraMark is fully embracing the trends toward digitization and increased accuracy through the use of AI in the clinical trial sector. Where do the opportunities and risks lie for agile investors?

Read

Commented by André Will-Laudien on July 14th, 2025 | 07:25 CEST

DAX correction! Biotech in takeover mode! BioNTech, CureVac, Pfizer, Vidac Pharma, and Kraft Heinz in focus

  • Biotechnology
  • Biotech
  • Pharma

The stock markets are in top form: both the DAX and the NASDAQ 100 have flexed their muscles in recent days. Prices are being driven primarily by the continued strength of technology stocks and growing hopes for stable global economic growth, despite Donald Trump's tariff madness. At the same time, a growing takeover fever in the biotechnology sector is providing additional momentum. In the field of cancer research in particular, companies such as BioNTech, Moderna, and other specialized mRNA players such as CureVac are increasingly becoming the focus of strategic investors. The fight against cancer is increasingly becoming one of the key drivers for new partnerships and market consolidation. Speculation about possible mergers and billion-dollar acquisitions is currently on the rise again. This opens up an exciting environment for investors, offering opportunities for above-average returns. We identify the trigger points.

Read

Commented by Fabian Lorenz on July 11th, 2025 | 07:20 CEST

Biotech takeover merry-go-round picks up speed! BioNTech, Evotec, Merck, and BioNxt Solutions!

  • Biotechnology
  • Biotech
  • Pharma

The takeover merry-go-round is spinning faster again in the biotech sector. The latest example is Merck's acquisition of Verona Pharma. The US group is paying USD 10 billion for the deal. BioNxt Solutions would be significantly cheaper to acquire at present. The Company aims to make it easier to take medication with melt films, skin patches, and tablets. In addition, it has now announced an exciting platform. The goal is to develop smarter chemotherapy, which, in turn, could create a billion-dollar market. And what are BioNTech and Evotec doing? Things have quieted down a bit at the German biotech leader following its billion-dollar deal with Bristol-Myers Squibb. However, analysts recommend buying the stock. Evotec, on the other hand, is languishing at around EUR 7. Can the quarterly figures provide new impetus for the struggling stock?

Read

Commented by Nico Popp on July 10th, 2025 | 07:25 CEST

Small-cap disrupts billion-dollar market: Johnson & Johnson, Merck KGaA, and NetraMark

  • Biotechnology
  • Biotech
  • AI
  • healthtech

When it comes to making people healthy, progress is what matters most. New drugs must be better and safer than old ones. To ensure that these requirements are met, comprehensive testing procedures are carried out by drug regulatory authorities. However, despite ever-expanding knowledge and modern methods, almost 90% of clinical trials still fail. When considering that the development of a drug costs an average of USD 2.6 billion and usually takes more than ten years, it becomes clear what a risk biotech companies and pharmaceutical multinationals are taking. This is precisely where NetraMark's business model comes in, offering the entire industry unparalleled leverage.

Read

Commented by Armin Schulz on July 10th, 2025 | 07:15 CEST

How BioNTech, PanGenomic Health, and Pfizer are using artificial intelligence to cut costs and boost returns

  • Biotechnology
  • healthtech
  • Biotech
  • AI

Digitalization is revolutionizing the biotechnology and pharmaceutical industries. Artificial intelligence sifts through billions of pieces of medical data in real time, accelerating drug development by years. This is also demonstrated by the new alliance between Moderna and Google Cloud, which are jointly developing an AI platform for customized mRNA cancer therapies. These technologies reduce production costs by up to 40% and generate disruptive return opportunities. At the same time, personalized medicine is opening up billion-dollar markets. Three companies are turning to artificial intelligence to boost their returns: BioNTech, PanGenomic Health, and Pfizer.

Read

Commented by Armin Schulz on July 9th, 2025 | 07:05 CEST

Liver cancer breakthrough fuels billion-dollar market: How Bayer, Vidac Pharma, and Novo Nordisk can now power your portfolio

  • Biotechnology
  • Biotech
  • Pharma
  • Innovations

The pharmaceutical industry is undergoing its biggest upheaval in decades. Megatrends such as cancer treatment, fueled by recent breakthroughs like the EMA approval of the liver cancer therapy Lenvima®/Keytruda®, and revolutionary therapies for diabetes and obesity are generating billion-dollar markets. Those who understand these growth drivers will identify lucrative opportunities. Innovative active ingredients are not only changing medicine but also unlocking exceptional return potential for forward-thinking investors. This dynamic draws attention directly to the strategies of Bayer, Vidac Pharma, and Novo Nordisk.

Read